Current concepts in immunology

  • Robert K. Oldham


The main function of the immune system is to protect the host from certain death due to numerous potential pathogens present in the environment. The development and maintenance of immunity is dependent on a complex and highly sophisticated defense organization functionally divided into the innate and adaptive immune systems.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Allison JP, Lanier LL. Structure, function and serology of the T-cell antigen receptor complex. Annu Rev Immunol 1987; 5: 503–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Asherson GL, Colizzi V, Zembala M. An overview of T-suppressor cell circuits. Annu Rev Immunol 1986; 4: 37–68.PubMedCrossRefGoogle Scholar
  3. 3.
    Baehner RL, Boxer LA, Davis J. The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood 1976; 48: 309–13.PubMedGoogle Scholar
  4. 4.
    Barlozzari T, Reynolds CW, Herberman RB. In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1- treated rats. J Immunol 1983; 131: 1024–7.PubMedGoogle Scholar
  5. 5.
    Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84: 9238–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Bich Thuy LT, Dukovich M, Peffer NJ et al. Direct activation of human resting T cells by IL 2: the role of an Il 2 receptor distinct from the Tac protein. J Immunol 1987; 139: 1550–6.PubMedGoogle Scholar
  7. 7.
    Bierer BE, Mentzer SJ, Greenstein JL, Burakoff SJ. The role of functional cell surface antigens in T cell activation. Year Immunol 1986; 2: 39–59.PubMedGoogle Scholar
  8. 8.
    Buckley CE III. Delayed hypersensitivity skin testing. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology, 1986: 259–73.Google Scholar
  9. 9.
    Carpenter CB, Lymphocyte-mediated cytotoxicity. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society of Microbiology, 1986: 304–7.Google Scholar
  10. 10.
    Ceuppens JL, Baroja ML, Lorre K et al. Human T cell activation with phytohemagglutinin. The function of IL-6 as an accessory signal. J Immunol 1988; 141: 3868–74.PubMedGoogle Scholar
  11. 11.
    Chiu CP, Moulds C, Coffman RL et al. Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells. Proc Natl Acad Sci USA 1988; 85: 7099–103.PubMedCrossRefGoogle Scholar
  12. 12.
    Clevers H, Alarcon B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 1988; 6: 629–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. Science 1989; 243: 355–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Crump WL III, Own Schaub LB, Grimm EA. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res 1989; 49: 149–53.PubMedGoogle Scholar
  15. 15.
    Dean JH, Connor R, Herberman RB et al. The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients to mitogens and alloantigens. Int J Cancer 1977; 20: 359–70.PubMedCrossRefGoogle Scholar
  16. 16.
    Dillman RO, Oldham RK, Tauer KW et al. Continuous interleukin-2 and lymphokine activated killer cells for advanced cancer: an NBSG trial. J Clin Oncol 1991; 9: 1233–40.PubMedGoogle Scholar
  17. 17.
    Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44: 153–206.PubMedCrossRefGoogle Scholar
  18. 18.
    Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317: 940–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Dorf ME, Benacerraf B. Suppressor cells and immunoregulation. Annu Rev Immunol 1984; 2: 127–57.PubMedCrossRefGoogle Scholar
  20. 20.
    Dukovich M, Wano Y, Le thi BT et al. A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature 1987; 327: 518–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Durum SK, Schmidt JA, Oppenheim JJ. Interleukin 1: an immunological perspective. Annu Rev Immunol 1985; 3: 263–87.PubMedCrossRefGoogle Scholar
  22. 22.
    Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule- (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988; 107: 321–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Dvorak HF, Galli SJ, Dvorak AM. Cellular and vascular manifestations of cell-mediated immunity. Hum Pathol 1986; 17: 122–37.PubMedCrossRefGoogle Scholar
  24. 24.
    Falkoff RJ, Butler JL, Dinarello CA, Fauci AS. Direct effects of a monoclonal B cell differentiation factor and of purified interleukin 1 on B cell differentiation. J Immunol 1984; 133: 692–6.PubMedGoogle Scholar
  25. 25.
    Fauci AS, Pratt KR. Activation of human B lymphocytes. I. Direct plaque-forming cell assay for the measurement of polyclonal activation and antigenic stimulation of human B lymphocytes. J Exp Med 1976; 144: 674–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Gallin JI, Quie PG. Leukocyte Chemotaxis: Methods, Physiology and Clinical Implications. New York: Raven Press, 1978.Google Scholar
  27. 27.
    Ganser A, Ottmann OG, Erdmann H et al. The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia. Ann Intern Med 1989; 111: 887–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Gearing AJ, Johnstone AP, Thorpe R. Production and assay of the interleukins. J Immunol Meth 1985; 83: 1–27.CrossRefGoogle Scholar
  29. 29.
    Geller RL, Gromo G, Inverardi L et al. Stepwise activation of T cells. Role of the calcium ionophore A23187. J Immunol 1987; 139: 3930–4.PubMedGoogle Scholar
  30. 30.
    Gillis S. Interleukin 2: biology and biochemistry. J Clin Immunol 1983; 3: 1–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Goldfarb RH, Serrate SA. Natural killer cells. In: Yoshida T, ed. Investigation of Cell-Mediated Immunity. New York: Churchill-Livingstone, 1985: 65–80.Google Scholar
  32. 32.
    Grey HM, Sette A, Buus S. How T cells see antigen. Sci Am 1989; 261: 56–64.PubMedCrossRefGoogle Scholar
  33. 33.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Grimm EA, Owen Schaub LB, Loudon WG, Yagita M. Lymphokine-activated killer cells. Induction and function. Ann NY Acad Sci 1988; 532: 380–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Gromo G, Geller RL, Inverardi L, Bach FH. Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes. Nature 1987; 327: 424–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Gromo G, Inverardi L, Geller RL et al. The stepwise activation of cytotoxic T lymphocytes. Immunol Today 1987; 8: 259–61.CrossRefGoogle Scholar
  37. 37.
    Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 1989; 321: 1449–59.PubMedCrossRefGoogle Scholar
  38. 38.
    Han X, Itoh K, Balch CM, Pellis NR. Recombinant interleukin 2 (RIL-4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes. Lymphokine Res 1988; 7: 227–35.PubMedGoogle Scholar
  39. 39.
    Hanna N, Fidler IJ. Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 1980; 65: 801–9.PubMedGoogle Scholar
  40. 40.
    Harada N, Matsumoto M, Koyama N et al. T cell replacing factor/interleukin 5 induces not only B-cell growth and differentiation, but also increased expression of interleukin 2 receptor on activated B-cells. Immunol Lett 1987; 15: 205–15.PubMedCrossRefGoogle Scholar
  41. 41.
    Haynes BF. Human T lymphocyte antigens as defined by monoclonal antibodies. Immunol Rev 1981; 57: 127–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Henkart PA. Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol 1985; 3: 31–58.PubMedCrossRefGoogle Scholar
  43. 43.
    Henkart PA, Millard PJ, Reynolds CW, Henkart MP. Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med 1984; 160: 75–93.PubMedCrossRefGoogle Scholar
  44. 44.
    Herberman RB, Thurman GB. Approaches to the immunological monitoring of cancer patients treated with natural or recombinant interferons. J Biol Response Modif 1983; 2: 548–62.Google Scholar
  45. 45.
    Hirano T, Taga T, Yamasaki K et al. A multifunctional cytokine (IL-6/BSF-2) and its receptor. Int Arch Allergy Appl Immunol 1989; 88: 29–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Hong R. Immunodeficiency. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology, 1986: 702–22.Google Scholar
  47. 47.
    Horiguchi J, Sariban E, Kufe D. Transcriptional and post-transcriptional regulation of CSF-1 gene expression in human monocytes. Mol Cell Biol 1988; 8: 3951–4.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Howard M, Farrar J, Hilfiker M et al. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med 1982; 155: 914–23.PubMedCrossRefGoogle Scholar
  49. 49.
    IUIS-WHO Nomenclature Subcommittee. Announcement. J Immunol 1985; 134: 659–60.Google Scholar
  50. 50.
    Johnson HM. Modulation of the immune response by interferons and their inducers. In: Mihick E, ed. Immunological Approaches to Cancer Therapeutics. New York: Wiley, 1982; 241–56.Google Scholar
  51. 51.
    Kawase I, Urdal DL, Brooks CG, Henney CS. Selective depletion of NK cell activity in vivo and its effect on the growth of NK- sensitive and NK- resistant tumor cell variants. Int J Cancer 1982; 29: 567–74.PubMedCrossRefGoogle Scholar
  52. 52.
    Kehrl JH, Muraguchi A, Butler JL et al. Human B cell activation, proliferation and differentiation. Immunol Rev 1984; 78: 75–96.PubMedCrossRefGoogle Scholar
  53. 53.
    Kishimoto T. Factors affecting B-cell growth and differentiation. Annu Rev Immunol 1985; 3: 133–57.PubMedCrossRefGoogle Scholar
  54. 54.
    Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. J Clin Invest 1983; 72: 304–15.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Koj A. The role of interleukin-6 as the hepatocyte stimulating factor in the network of inflammatory cytokines. Ann NYAcad Sci 1989; 557: 1–8.CrossRefGoogle Scholar
  56. 56.
    Kovacs EJ, Beckner SK, Longo DL et al. Cytokine gene expression during the generation of human lymphokine-activated killer cells: Early induction of interleukin 10 by interleukin 2. Cancer Res 1989; 49: 940–4.PubMedGoogle Scholar
  57. 57.
    Kumar A, Moreau JL, Baran D, Theze J. Evidence for negative regulation of T cell growth by low affinity interleukin 2 receptors. J Immunol 1987; 138: 1485–93.PubMedGoogle Scholar
  58. 58.
    Kupfer A, Singer SJ. Cell biology of cytotoxic and helper T cell functions: immunofluorescence microscopic studies of single cells and cell couples. Annu Rev Immunol 1989; 7: 309–37.PubMedCrossRefGoogle Scholar
  59. 59.
    Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 1985; 135: 4273–80.PubMedGoogle Scholar
  60. 60.
    Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 1985; 45: 3735–41.PubMedGoogle Scholar
  61. 61.
    Landay A, Gartland GL, Clement LT. Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses. J Immunol 1983; 131: 2757–61.PubMedGoogle Scholar
  62. 62.
    Lasser A. The mononuclear phagocytic system: a review. Hum Pathol 1983; 14: 108–26.PubMedCrossRefGoogle Scholar
  63. 63.
    Lipton JN, Nathan DJ. Interactions between lymphocytes and macrophages in hematopoiesis. In: Golde DW, TakakuGoogle Scholar
  64. F, eds. Hematopoietic Stem Cells. New York: Marcel Dekker, 1980: 145–202.Google Scholar
  65. 64.
    Lotzova E, Herberman RB. Immunobiology of Natural Killer Cells. Boca Raton, FL: CRC Press, 1986.Google Scholar
  66. 65.
    Lu L, Welte K, Gabrilove JL et al. Effects of recombinant human tumor necrosis factor alpha, recombinant human gamma-interferon, and prostaglandin E on colony formation of human hematopoietic progenitor cells stimulated by natural human pluripotent colony-stimulating factor, pluripoietin alpha, and recombinant erythropoietin in serum-free cultures. Cancer Res 1986; 46: 4357–61.Google Scholar
  67. 66.
    Maluish AE, Strong DM. Lymphocyte proliferation. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society of Microbiology, 1986: 274–81.Google Scholar
  68. 67.
    Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235–54.PubMedCrossRefGoogle Scholar
  69. 68.
    Meriney DK. Methodology of immunologic assays relating to humoral components. In: Grieco MH, Meriney DK, eds. Immunodiagnosis for Clinicians. Chicago: Year Book Medical Publishers, 1983: 19–39.Google Scholar
  70. 69.
    Meuer SC, Acuto O, Hercent T, Schlossman SF, Reinherz EL. The human T-cell receptor. Annu Rev Immunol 1984; 2: 23–50.PubMedCrossRefGoogle Scholar
  71. 70.
    Michel RH, Pancake SJ, Noseworthy J, Karnovsky ML. Measurement of rates of phagocytosis: the use of cellular monolayers. J Cell Biol 1969; 40: 216–24.CrossRefGoogle Scholar
  72. 71.
    Millard PJ, Henkart MP, Reynolds CW, Henkart PA. Purification and properties of cytoplasmic granules from cytotoxic rat LGL tumors. J Immunol 1984; 132: 3197–204.PubMedGoogle Scholar
  73. 72.
    Miyajima A, Miyatake S, Schreurs J, et al. Coordinate regulation of immune and inflammatory responses by T cell-derived lymphokines. FASEB J 1988; 2: 2462–73.PubMedGoogle Scholar
  74. 73.
    Moller G. Concanavalin-A-activated lymphocytes suppress immune responses in vitro but are helper cells in vivo. Scand J Immunol 1985; 21: 31–4.PubMedCrossRefGoogle Scholar
  75. 74.
    Morimoto C, Letvin NL, Boyd AW et al. The isolation and characterization of the human helper inducer T cell subset. J Immunol 1985; 134: 3762–9.PubMedGoogle Scholar
  76. 75.
    Morimoto C, Letvin NL, Distaso JA et al. The isolation and characterization of the human suppressor inducer T cell subset. J Immunol 1985; 134: 1508–15.PubMedGoogle Scholar
  77. 76.
    Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–73.PubMedCrossRefGoogle Scholar
  78. 77.
    Mule JJ, Shu S, Rosenberg SA. The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 1985; 135: 646–52.PubMedGoogle Scholar
  79. 78.
    Muller Eberhard HJ. The molecular basis of target cell killing by human lymphocytes and of killer cell self-protection. Immunol Rev 1988; 103: 87–98.PubMedCrossRefGoogle Scholar
  80. 79.
    Munthe-Kaas AC, Kaplan G. Endocytosis by macrophages. In: Carr I, Daems WT, eds. The Reticuloendothelial System: A Comprehensive Treatise. New York: Plenum, 1980: 19–55.Google Scholar
  81. 80.
    Nagler A, Lanier LL, Phillips JH. The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. J Immunol 1988; 141: 2349–51.PubMedGoogle Scholar
  82. 81.
    Nakanishi K, Malek TR, Smith KA et al. Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis. J Exp Med 1984; 160: 1605–21.PubMedCrossRefGoogle Scholar
  83. 82.
    Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79: 319–26.PubMedCentralPubMedCrossRefGoogle Scholar
  84. 83.
    Neckers LM, Cossman J. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl Acad Sci USA 1983; 80: 3494–8.PubMedCrossRefGoogle Scholar
  85. 84.
    Ochoa AC, Gromo G, Alter BJ, et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol 1987; 138: 2728–33.PubMedGoogle Scholar
  86. 85.
    Ochoa AC, Hasz DE, Rezonzew R et al. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: Identification and isolation of effector subsets. Cancer Res 1989; 49: 963–8.PubMedGoogle Scholar
  87. 86.
    OGarra A, Umland S, DeFrance T, Christiansen J. `B-cell factors’ are pleiotropic. Immunol Today 1988; 9: 45–54.CrossRefGoogle Scholar
  88. 87.
    OGarra A, Warren DJ, Sanderson CJ et al. Interleukin-4 (B cell growth factor-II/eosinophil differentiation factor) is a mitogen and differentiation factor for preactivated murine B lymphocytes. Curr Top Microbiol Immunol 1986; 132: 133–41.Google Scholar
  89. 88.
    Oldham RK. Natural killer cells: history and significance. J Biol Response Modif 1982; 1: 217–31.Google Scholar
  90. 89.
    Oldham RK. NK cells: artifact to reality, an odyssey in biology. Can Metas Rev 1983; 2: 232–336.Google Scholar
  91. 90.
    Oldham RK, Gail MH, Baker MA et al. Immunological studies in a double blind randomized trial comparing intrapleural BCG against placebo in patients with resected stage I non-small cell lung cancer. Cancer Immunol Immunother 1982; 13: 164–73.PubMedCrossRefGoogle Scholar
  92. 91.
    Oldham RK, Weese JL, Herberman RB et al. Immunological monitoring and immunotherapy in carcinoma of the lung. Int J Cancer 1976; 18: 739–49.CrossRefGoogle Scholar
  93. 92.
    Ortaldo JR, Herberman RB. Heterogeneity of natural killer cells. Annu Rev Immunol 1984; 2: 359–94.PubMedCrossRefGoogle Scholar
  94. 93.
    Ortaldo JR, Mason A, Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 1986; 164: 1193–205.PubMedCrossRefGoogle Scholar
  95. 94.
    Owen-Schaub L, Yagita M, Tsudo M et al. Evidence for distinct IL-2 receptors in induction versus maintenance of LAK function. Ann NY Acad Sci 1988; 532: 480–1.CrossRefGoogle Scholar
  96. 95.
    Paetkau V, Bleackley RC, Riendeau D et al. Toward the molecular biology of IL-2. Contemp Top Mol Immunol 1985; 10: 35–61.PubMedGoogle Scholar
  97. 96.
    Palacios R, Henson G, Steinmetz M, McKearn JP. Interleukin-3 supports growth of mouse pre-B-cell clones in vitro. Nature 1984; 309: 126–31.PubMedCrossRefGoogle Scholar
  98. 97.
    Pasternack MS, Verret CR, Liu MA, Eisen HN. Serine esterase in cytolytic T lymphocytes. Nature 1986; 322: 740–3.PubMedCrossRefGoogle Scholar
  99. 98.
    Perlmutter DH. IFNO2/IL-6 is one of several cytokines that modulate acute phase gene expression in human hepatocytes and human macrophages. Ann NY Acad Sci 1989; 557: 332–42.PubMedCrossRefGoogle Scholar
  100. 99.
    Platt JL, Grant BW, Eddy AA, Michael AF. Immune cell populations in cutaneous delayed-type hypersensitivity. J Exp Med 1983; 158: 1227–42.PubMedCrossRefGoogle Scholar
  101. 100.
    Poulter LW, Seymour GJ, Duke O et al. Immunohistological analysis of delayed-type hypersensitivity in man. Cell Immunol 1982; 74: 358–69.PubMedCrossRefGoogle Scholar
  102. 101.
    Raulet DH. The structure, function, and molecular genetics of the gamma/delta T cell receptor. Annu Rev Immunol 1989; 7: 175–207.PubMedCrossRefGoogle Scholar
  103. 102.
    Reed JC, Alpers JD, Nowell PC, Hoover RG. Sequential expression of proto-oncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci USA 1986; 83: 3982–6.PubMedCrossRefGoogle Scholar
  104. 103.
    Reed JC, Prystowsky MB, Kern JA et al. Regulation of proto-oncogene expression during lymphocyte activation and proliferation. In: Gupta S, Paul WE, Fauci AS, eds. Advances in Experimental Medicine and Biology. New York: Plenum Press, 1986: 249–62.Google Scholar
  105. 104.
    Reinherz EL, Schlossman SF. Current concepts in immunology: regulation of the immune response - inducer andGoogle Scholar
  106. suppressor T-lymphocyte subsets in human beings. N Engl J Med 1980; 303: 370–3.CrossRefGoogle Scholar
  107. 105.
    Reinherz EL, Schlossman SF. The characterization and function of human immunoregulatory T lymphocyte subsets. Immunol Today 1981; 2: 69–73.CrossRefGoogle Scholar
  108. 106.
    Robb RJ, Greene WC, Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor. J Exp Med 1987; 165: 1201–6.PubMedCrossRefGoogle Scholar
  109. 107.
    Robb RJ, Rusk CM, Yodoi J, Greene WC. Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci USA 1987; 84: 2002–6.PubMedCrossRefGoogle Scholar
  110. 108.
    Rocklin RE, Meyers OL, David JR. An in vitro assay for cellular hypersensitivity in man. J Immunol 1970; 104: 95–102.PubMedGoogle Scholar
  111. 109.
    Rosenberg SA, Eberlein TJ, Grimm EA et al. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. Surgery 1982; 92: 328–36.PubMedGoogle Scholar
  112. 110.
    Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.PubMedCrossRefGoogle Scholar
  113. 111.
    Rosenberg SA, Mule JJ. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2. Surgery 1985; 98: 437–44.PubMedGoogle Scholar
  114. 112.
    Rosenberg SA, Mule JJ, Spiess PJ et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161: 1169–88.PubMedCrossRefGoogle Scholar
  115. 113.
    Rosenblum MG, Donato NJ. Tumor necrosis factor a: a multifaceted peptide hormone. CRC Crit Rev Immunol 1989; 9: 21–44.Google Scholar
  116. 114.
    Sakane T, Green I. Human suppressor T cells induced by concanavalin A: suppressor T cells belong to distinctive T cell subclasses. J Immunol 1977; 119: 1169–78.PubMedGoogle Scholar
  117. 115.
    Schatten S, Granstein RD, Drebin JA, Greene MI. Suppressor T cells and the immune response to tumors. CRC Crit Rev Immunol 1984; 4: 335–79.Google Scholar
  118. 116.
    Schlick E, Hartung K, Stevenson HC, Chirigos MA. Secretion of colony-stimulating factors by human monocytes and bone marrow cells after in vitro treatment with biological response modifiers. J Leuk Biol 1985; 37: 615–27.Google Scholar
  119. 117.
    Schwartz RH. T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. Annu Rev Immunol 1985; 3: 237–61.PubMedCrossRefGoogle Scholar
  120. 118.
    Shipp MA, Reinherz EL. Differential expression of nuclear proto-oncogenes in T cells triggered with mitogenic and non-mitogenic T3 and T11 activation signals. J Immunol 1987; 139: 2143–8.PubMedGoogle Scholar
  121. 119.
    Sieff CA. Hematopoietic growth factors. J Clin Invest 1987; 79: 1549–57.PubMedCentralPubMedCrossRefGoogle Scholar
  122. 120.
    Smith CW, Rothlein R, Hughes BJ et al. Recognition of an endothelial determinant for CD 18-dependent human neutrophil adherence and transendothelial migration. J Clin Invest 1988; 82: 1746–56.PubMedCentralPubMedCrossRefGoogle Scholar
  123. 121.
    Smith KA. Dissection of the molecular events occurring during T cell cycle progression. In: Gupta S, Paul WE, and Fauci AS, eds. Advances in Experimental Medicine and Biology. New York: Plenum Press, 1986: 125–8.Google Scholar
  124. 122.
    Smith KA. The interleukin 2 receptor. Adv Immunol 1988; 42: 165–79.PubMedCrossRefGoogle Scholar
  125. 123.
    Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169–76.PubMedCrossRefGoogle Scholar
  126. 124.
    Spencer RP, Pearson HH. Radionuclide Studies of the Spleen. Cleveland: CRC Press, 1975.Google Scholar
  127. 125.
    Springer TA, Dustin ML, Kishimoto TK, Marlin SD. The lymphocyte function-associated LFA-1, CD2, and LFA-3Google Scholar
  128. molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 1987; 5: 223–52.Google Scholar
  129. 126.
    Springer TA, Unkeless JC. Analysis of macrophage differentiation and function with monoclonal antibodies. Con-temp Top Immunobiol 1984; 13: 1–31.Google Scholar
  130. 127.
    Taniguchi T. Regulation of cytokine gene expression. Annu Rev Immunol 1988; 6: 439–64.PubMedCrossRefGoogle Scholar
  131. 128.
    Te Velde AA, yard BA, Klomp JP et al. Modulation of phenotypic and functional properties of human peripheral blood monocytes by interleukin-2 (IL-4). Agents Actions 1989; 26: 199–200.CrossRefGoogle Scholar
  132. 129.
    Teshigawara K, Wang HM, Kato K, Smith KA. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med 1987; 165: 223–38.PubMedCrossRefGoogle Scholar
  133. 130.
    Tosato G, Pike SE. Interferon-beta 2/interleukin 6 is a co-stimulant for human T lymphocytes. J Immunol 1988; 141: 1556–62.PubMedGoogle Scholar
  134. 131.
    Tracey DE. Macrophage mediated injury. In: Rose NR, Siegel BV, eds. The Reticuloendothelial System: A Comprehensive Treatise. New York: Plenum Press, 1983: 77–101.Google Scholar
  135. 132.
    Trinchieri G, Perussa B. Human natural killer cells: biologic and pathologic aspects. Lab Invest 1984; 50: 489–513.PubMedGoogle Scholar
  136. 133.
    Tsudo M, Kozak RW, Goldman CK, Waldmann TA. Demonstration of a non-Tac peptide that binds interleukinGoogle Scholar
  137. 2:.
    a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci USA 1986; 83: 9694–8.Google Scholar
  138. 134.
    Unanue ER. Antigen-presenting function of the macrophage. Annu Rev Immunol 1984; 2: 395–428.PubMedCrossRefGoogle Scholar
  139. 135.
    Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-ß. Immunol Today 1989; 10: 258–61.PubMedCrossRefGoogle Scholar
  140. 136.
    Waldmann TA, Broder S. Suppressor cells in the regulation of the immune response. Prog Clin Immunol 1977; 3: 155–99.PubMedGoogle Scholar
  141. 137.
    Weiss A, Imboden JB. Cell surface molecules and early events involved in human T lymphocyte activation. Adv Immunol 1987; 41: 1–38.PubMedCrossRefGoogle Scholar
  142. 138.
    Weissman AM, Harford JB, Svetlik PB et al. Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Proc Natl Acad Sci USA 1986; 83: 1463–6.PubMedCrossRefGoogle Scholar
  143. 139.
    West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905.PubMedCrossRefGoogle Scholar
  144. 140.
    Whitlock C, Denis K, Robertson D, Witte O. In vitro analysis of murine-B-cell development. Annu Rev Immunol 1985; 3: 213–35.PubMedCrossRefGoogle Scholar
  145. 141.
    Woodruff JJ, Clarke LM, Chin YH. Specific cell-adhesion mechanisms determining migration pathways of recirculating lymphocytes. Annu Rev Immunol 1987; 5: 201–22.PubMedCrossRefGoogle Scholar
  146. 142.
    Yang SC, Owen Schaub L, Grimm EA, Roth JA. Induction of lymphokine-activated killer cytotoxicity with interleukin2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother 1989; 29: 193–8.PubMedCrossRefGoogle Scholar
  147. 143.
    Young JD, Liu C. Multiple mechanisms of lymphocyte mediated killing. Immunol Today 1988; 9: 140–4.PubMedCrossRefGoogle Scholar
  148. 144.
    Zlotnik A, Fischer M, Roehm N, Zipori D. Evidence for effects of interleukin 4 (B cell stimulatory factor 1) on macrophages: enhancement of antigen presenting ability of bone marrow-derived macrophages. J Immunol 1987; 138: 4275–9.PubMedGoogle Scholar
  149. 145.
    Zola H. The surface antigens of human B lymphocytes. Immunol Today 1987; 8: 308–10.CrossRefGoogle Scholar
  150. 146.
    Zucali JR, Broxmeyer HE, Gross MA, Dinarello CA. Recombinant human tumor necrosis factors alpha and beta stimulate fibroblasts to produce hemopoietic growth factors in vitro. J Immunol 1988; 140: 840–4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Robert K. Oldham

There are no affiliations available

Personalised recommendations